Clinical Trials Logo
  1. Home
  2. Gastric Cancer
  3. NCT05901376
  4. Details
NCT05901376 Clinical Trial

MicroRNAs From Blood Samples as Biomarkers for Gastric Cancer Detection

Gastric Cancer Clinical Trial

Official title:
MicroRNAs From Blood Samples as Biomarkers for Gastric Cancer Detection: a Diagnostic Study

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05901376
Other study ID # RP023
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 25, 2023
Est. completion date June 2025

Study information
Verified date June 2023
Source King Chulalongkorn Memorial Hospital
Contact Rapat Pittayanon
Phone +662564000
Email rapat125@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to compare specific microRNA levels from the plasma of gastric cancer patients and healthy volunteers to see if there is an upregulated expression in gastric cancer patients. The main question it aims to answer is: - Can microRNAs be effectively used as diagnostic biomarkers for gastric cancer? Participants will be asked for their consent to obtain 5 cc of blood.

Recruitment information / eligibility
Status Recruiting
Enrollment 280
Est. completion date June 2025
Est. primary completion date January 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria for Gastric Cancer group: - Recently diagnosed gastric cancer - Never received any treatment for gastric cancer Inclusion Criteria for Control group: - Age 50 or above - Underwent elective upper gastrointestinal endoscopy and negative for gastric cancer - No prior history of gastric dysplasia or cancer Exclusion Criteria: - Patients who cannot give informed consent - Pregnancy - Lymphoma

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• MicroRNA
MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223

Locations
Country Name City State
Thailand King Chulalongkorn Memorial Hospital Bangkok Not Required For This Country

Sponsors (1)
Lead Sponsor Collaborator
King Chulalongkorn Memorial Hospital

Country where clinical trial is conducted

Thailand, 

Outcome
Type Measure Description Time frame Safety issue
Primary The different of MiR-20a level between gastric cancer and control group The different of MiR-20a level between gastric cancer and control group Day 1
Primary The different of MiR-21 level between gastric cancer and control group The different of MiR-21 level between gastric cancer and control group Day 1
Primary The different of MiR-106b level between gastric cancer and control group The different of MiR-106b level between gastric cancer and control group Day 1
Primary The different of MiR-199a level between gastric cancer and control group The different of MiR-199a level between gastric cancer and control group Day 1
Primary The different of MiR-223 level between gastric cancer and control group The different of MiR-223 level between gastric cancer and control group Day 1
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2